Celgene Escapes Revlimid, Thalomid Antitrust Lawsuit, for Now

Celgene Corp. convinced a federal district court to dismiss claims by insurers and others alleging the drugmaker excluded generic entry into the market for the drugs Revlimid and Thalomid.

The insurers and MSP Recovery Claims Series LLC failed to show that Celgene possessed monopoly power and that it willfully used that power to prevent growth or development in the market, Judge Esther Salas said Thursday for the US District Court for the District of New Jersey.

The insurers and MSP accused Celgene, a Bristol-Myers Squibb Co. subsidiary, of using an array of anti-competitive tactics to corner the market for Thalomid, ...